



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.
Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.
E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Date: 12.08.2023

To,
The Department of Corporate Services,
BSE Limited.
Floor No. 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Scrip Code: 524400

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on 12th August, 2023

Pursuant to the regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e.12th August, 2023 have

1. Approved the Unaudited Financial Results of the Company for the quarter ended 30th June, 2023.

We enclose herewith the Limited Review Report of the Unaudited Financial Results of the Company for the quarter ended 30th June, 2023 issued by the Statutory Auditors of the Company.

The meeting was commenced at 6.30 p.m. and concluded at 7.20 p.m.

Please take the above details on your records.

Thanking You.

For, Ishita Drugs and Industries Limited

Jagdish Agrawal
Managing Director

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054
D & B D-U-N-S Number - 65-018-0359



Date: 12/08/2023

To,
The Board of Directors,
Ishita Drugs & Industries Limited,
Ahmedabad.

LIMITED REVIEW REPORT

We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period **01 Apr 2023 to 30 Jun 2023**. (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of **Interim financial information performed by the Independent auditor of the entity issued by the Institute of Chartered Accountants of India**. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act, 2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
JAYMIN SHAH & ASSOCIATES

Chartered Accountants M No. 170863

CA Mayank Sancheti

M No. :170863

Date: 12/08/2023

Place: Ahmedabad

UDIN: 23170863BGRDES9625

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

Unaudited Financial Results for the Quarter Ended June 30, 2023

Amount in Lacs except Per Share data

Particulars	Figures for 3 Months Ended	Figures for Preceding 3 Months Ended	Figures for Corresponding 3 Months in the previous Year Ended	Figures for the previous year Ended
	Un-audited	Audited	Un-audited	Audited
	30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23
1 INCOME				
Revenue from Operations	308.63	262.66	335.36	1207.23
Other Income	7.43	8.80	3.64	20.05
Total Income	316.06	271.46	339.00	1227.29
2 EXPENSES				
(a) Cost of Material Consumed	223.67	172.04	213.30	820.52
(b) Purchase of Stock-In-Trade	0.00	-6.98	45.75	48.22
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(12.06)	10.23	(18.84)	(13.42)
(d) Employee Benefit Expense	31.10	35.03	29.63	128.35
(e) Finance Cost	2.61	4.45	0.36	5.36
(f) Depreciation, Depletion and Amortisation Expense	3.43	3.19	3.24	12.93
(g) Other Expense	49.07	28.39	43.44	147.38
Total Other Expenses	49.07	28.39	43.44	147.38
Total Expenses	297.82	246.36	316.88	1149.34
3 Total Profit before Exceptional Items and Tax	18.23	25.10	22.12	77.95
4 Exceptional Items	0.00	0.00	0.00	0.00
5 Total Profit before Tax	18.23	25.10	22.12	77.95
6 Tax Expense				
7 Current Tax	4.50	8.00	5.50	21.00
8 Deferred Tax	0.00	(0.80)	0.00	(0.80)
9 Total Tax Expenses	4.50	7.20	5.50	20.20
10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00
11 Net Profit Loss for the period from continuing operations	13.73	17.89	16.62	57.74

Jaydeep Agrawal



12	Profit / (Loss) from discontinued operations before tax	0.00	0.00	0.00	0.00
13	Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00
14	Net Profit / (Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00
15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00
16	Total Profit / (Loss) for the period	13.73	17.89	16.62	57.74
17	Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00
18	Total Comprehensive Income for the Period	13.73	17.89	16.62	57.74
19	Total profit or loss attributable to				
	Profit or loss, attributable to owners of parents	0.00	0.00	0.00	0.00
	Total Profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00
20	Total comprehensive income for the period attributable to				
	Comprehensive Income for the period attributable to the owners of parents	0.00	0.00	0.00	0.00
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.00	0.00	0.00	0.00
21	Details of Equity Share Capital				
	Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00
22	Details of Debt Securities				
	Paid-Up Debt Capital	0.00	0.00	0.00	0.00
	Face Value of Debt Securities	0.00	0.00	0.00	0.00
23	Reserves Excluding Revaluation Reserves	0.00	0.00	0.00	0.00
24	Debenture Redemption Reserve	0.00	0.00	0.00	0.00
25	Earnings Per Share				
(i)	Earnings Per Share for continuing operations				
	Basic Earnings / (Loss) per share from continuing operations	0.46	0.60	0.56	1.93
	Diluted Earnings / (Loss) per share from continuing operations	0.46	0.60	0.56	1.93
(ii)	Earnings Per Share for discontinued operations				
	Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00
	Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00
(iii)	Earnings per Equity Share				
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.46	0.60	0.56	1.93
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.46	0.60	0.56	1.93
26	Debt Equity Ratio	0.00	0.00	0.00	0.00
27	Debt Service Coverage Ratio	0.00	0.00	0.00	0.00
28	Interest Service Coverage Ratio	0.00	0.00	0.00	0.00

Japdin Agrawal



NOTES

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on August 12, 2023.
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter ended 30th June, 2023 are Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, **ISHITA DRUGS AND INDUSTRIES LIMITED****JAGDISH AGRAWAL****MANAGING DIRECTOR****DIN: 01031687**Place **Ahmedabad**Date **12-Aug-23**